Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Development programme

SURPASS — tirzepatide in type 2 diabetes — page 2

The glycaemic programme for tirzepatide across background therapies, including active comparisons against semaglutide, insulin degludec and insulin glargine, and an event-driven cardiovascular outcome trial.

Showing 0 records on this page

Records in this programme

27 documents · page 2 of 2

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SURPASS-CVOT-DDIprogramme recordTirzepatidePhase 1ReportedRandomised crossover—2025Very low
SURPASS-CVOT-PKprogramme recordTirzepatidePhase 1ReportedPhase 1 ascending dose—2025Very low
SURPASS-CVOT-RENAL-IMPprogramme recordTirzepatidePhase 1ReportedPhase 1 ascending dose—2025Very low

page 2 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.